Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sale of Prescription...

    Sale of Prescription Drugs give Bayer a 16 percent boost

    Written by savita thakur thakur Published On 2016-04-28T09:13:13+05:30  |  Updated On 28 April 2016 9:13 AM IST
    Sale of Prescription Drugs give Bayer a 16 percent boost

    Frankfurt : German drugmaker Bayer reported a 15.7 percent jump in underlying core earnings for the first quarter, boosted by sales of prescription drugs, such as anti-blindness treatment Eylea and stroke prevention pill Xarelto.


    First-quarter profit before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, rose to 3.4 billion euros ($3.8 billion), bolstered by growth at its farming pesticides and seeds business in North America.


    That was above average market expectations for 3.07 billion euros.


    "Pharma was driven by a good products performance despite higher investments in R&D (research and development). Crop Science was performing surprisingly well, given the weak seeds market condition," said Peter Spengler, an analyst at DZ Bank.


    The shares were seen 1.8 percent higher in pre-market trading at brokerage Lang & Schwarz.


    Bayer, the inventor of aspirin and maker of Yasmin birth control pills, said it still expected adjusted EBITDA to increase by a medium single-digit percentage this year, when excluding separately-listed plastics subsidiary Covestro , which it plans to divest on the open market.


    The group confirmed its full-year sales forecast, which it said now excludes Covestro, for about 35 billion euros, up from 2015 sales of 34.3 billion. ($1 = 0.8879 euros) (Editing by Victoria Bryan and Louise Heavens)




    amortisationanti blindnessdepressionDZ BankEBITDAinterestLouise HeavensPeter Spenglerprescription drugR&Dresearch and developmenttaxesVictoria Bryan
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok